Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Factors to consider when using haplo-SCT: donor selection criteria and source of stem cells

Arnon Nagler • 16 Apr 2024
EBMT 2024
General Cyclophosphamide

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses factors that should be considered for patients undergoing haploidentical stem cell transplantation (haplo-SCT). He highlights how donor selection criteria vary depending on whether anti-thymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCy) is utilized for immunosuppression. Additionally, Prof. Nagler compares bone marrow (BM) and peripheral blood (PB) as stem cell sources. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arnon Nagler

2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
2:02
Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023

Related Videos

4:09
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty • 17 Apr 2024
1:56
Addressing access inequality in CAR-T therapies
Francesca Del Bufalo • 15 Apr 2024
1:34
The future role of AI models in hematology and the need for high-quality data sets
Thomas Coats • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals